Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

  • Iacoboni García-Calvo, Gloria
  • Martinez-Cibrian, Nuria
  • Corral, Lucia Lopez
  • Sanchez, Jose M.
  • Abrisqueta, Pau
  • Barba Suñol, Pere
  • Bailén, Rebeca
  • Villacampa Javierre, Guillermo
Recerca clínica del càncer; Càncer hematològic; Limfoma no Hodgkin, Investigación clínica del cáncer; Cáncer hematológico; Linfoma no Hodgkin, Clinical cancer research; Hematological cancer; Non-Hodgkin's lymphoma, Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa-cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa-cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non-relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9 months. With a median follow-up of 14.1 months from CAR T-cell infusion, median progression-free survival and overall survival were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa-cel for patients with relapsed/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

  • Ortiz-Maldonado, Valentín
  • Urbano-Ispizua, Alvaro
  • Barba Suñol, Pere
  • Ljungman, Per
  • de la Camara, Rafael
  • Tridello, Gloria
  • Spanjaart, Anne Mea
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer hematològic; Malalties infeccioses, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer hematológico; Enfermedades infecciosas, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haematological cancer; Infectious diseases, COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients. For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it is known that COVID-19 leads to severe morbidity and high mortality as compared to the general population [1–3]. For patients treated with Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell malignancies however, descriptions of the clinical course and outcome are still limited to small case series and case reports [4–8]. CAR-T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. In order to rapidly inform the medical field on the impact of COVID-19 on CAR-T-cell therapy recipients, the EBMT Infectious Diseases Working Party and the EHA Lymphoma Group joined forces and present the clinical course of COVID-19 in the largest European cohort to date.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia

  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Morgades, Mireia|||0000-0003-0295-2534
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Gil, Cristina
  • Guàrdia, Ramón
  • Moreno, Maria José
  • Martínez-Carballeira, Daniel|||0000-0003-4840-7822
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • González Campos, José
  • González Gil, Celia|||0000-0002-7582-1482
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Ramirez, Jose Luis
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Artola, Maria Teresa
  • Cladera, Antonia
  • Tormo, Mar|||0000-0001-9622-1649
  • Bermúdez, Arancha
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Monsalvo, Silvia
  • Novo, Andrés
  • Cervera, Marta
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Junca, Jordi|||0000-0003-0142-772X
  • Ciudad Pizarro, Juana
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Bailén, Rebeca|||0000-0003-2838-1776
  • López Corral, Lucia|||0000-0003-1908-5596
  • Sánchez Pina, José María|||0000-0002-9181-0900
  • Guerreiro, Manuel
  • Caballero, Ana Carolina|||0000-0002-4950-5259
  • Mussetti, Alberto|||0000-0002-4088-036X
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Hernani, Rafael|||0000-0003-1043-8076
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Solano, Carlos|||0000-0003-3702-0817
  • Sureda, Anna|||0000-0002-1238-6970
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • Kwon, Mi|||0000-0002-3855-7774
  • Reguera-Ortega, Juan Luis
  • Barba, Pere|||0000-0001-7076-7969
Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa-cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa-cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non-relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9 months. With a median follow-up of 14.1 months from CAR T-cell infusion, median progression-free survival and overall survival were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa-cel for patients with relapsed/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses. This article provides real-world European data on the results of relapsed/refractory large B-cell lymphoma patients treated with tisagenlecleucel.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

  • Barba, Pere|||0000-0001-7076-7969
  • Morgades, Mireia|||0000-0003-0295-2534
  • Montesinos, Pau|||0000-0002-3275-5593
  • González Campos, José
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Gil, Cristina
  • Bernal, Teresa|||0000-0002-2338-513X
  • Tormo, Mar|||0000-0001-9622-1649
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Novoa, Sandra
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Queipo de Llano, M. Paz
  • Cervera, Marta
  • Coll, Rosa|||0000-0003-0560-1254
  • Bermúdez, Arancha
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Monsalvo, Silvia
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Garcia-Boyero, Raimundo
  • Novo, Andres
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Cladera, Antonia
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Serrano, Josefina
  • Artola, Maria Teresa
  • Soria, Beatriz
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Herrera, Pilar|||0000-0002-4118-7110
  • Barrios, Daniel
  • Ribera, Jose-Maria|||0000-0003-1042-6024
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

  • Ortiz-Maldonado, Valentín
  • Urbano-Ispizua, Alvaro
  • Barba Suñol, Pere
  • Ljungman, Per
  • de la Camara, Rafael
  • Tridello, Gloria
  • Spanjaart, Anne Mea
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer hematològic; Malalties infeccioses, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer hematológico; Enfermedades infecciosas, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haematological cancer; Infectious diseases, COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients. For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it is known that COVID-19 leads to severe morbidity and high mortality as compared to the general population [1–3]. For patients treated with Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell malignancies however, descriptions of the clinical course and outcome are still limited to small case series and case reports [4–8]. CAR-T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. In order to rapidly inform the medical field on the impact of COVID-19 on CAR-T-cell therapy recipients, the EBMT Infectious Diseases Working Party and the EHA Lymphoma Group joined forces and present the clinical course of COVID-19 in the largest European cohort to date.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

  • Iacoboni García-Calvo, Gloria
  • Martinez-Cibrian, Nuria
  • Corral, Lucia Lopez
  • Sanchez, Jose M.
  • Abrisqueta, Pau
  • Barba Suñol, Pere
  • Bailén, Rebeca
  • Villacampa Javierre, Guillermo
Recerca clínica del càncer; Càncer hematològic; Limfoma no Hodgkin, Investigación clínica del cáncer; Cáncer hematológico; Linfoma no Hodgkin, Clinical cancer research; Hematological cancer; Non-Hodgkin's lymphoma, Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa-cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa-cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non-relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9 months. With a median follow-up of 14.1 months from CAR T-cell infusion, median progression-free survival and overall survival were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa-cel for patients with relapsed/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses.